Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Protein Kinase Inhibitors (PKIs) and Histone Deacetylase Inhibitors (HDACIs) are key anticancer agents.
• Cancer's multifactorial nature necessitates targeting multiple pathways for effective treatment.
• Multi-target drugs offer advantages by simultaneously modulating several signaling pathways.

Purpose of the Study:

• To review the recent literature on the development of multi-target kinase-HDAC inhibitors.
• To discuss the challenges and future directions in this field.

Main Methods:

• Literature review of scientific publications on dual PKI-HDACI agents.
• Analysis of synergistic effects observed in combined kinase inhibitor and HDAC inhibitor therapies.

Main Results:

• Synergistic anticancer effects have been observed with combinations of specific kinase inhibitors (e.g., imatinib, dasatinib, sorafenib) and HDAC inhibitors (e.g., vorinostat, romidepsin, panobinostat).
• A significant number of multi-target agents integrating PKI and HDACI functionalities have been developed.

Conclusions:

• Multi-target agents combining PKIs and HDACIs represent a promising strategy for treating complex cancers.
• Further research and development are needed to overcome challenges and optimize these dual-action therapies.